• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Nanoparticles

Polymeric nanoparticles transport quantum dots into cells

November 1, 2016 By Sarah Faulkner

Researchers from the University of Tokyo treated the surfaces of nanoparticles with polymers and enabled the transport of quantum dots into cells, according to a study published in Science and Technology of Advanced Materials. By coating nanoparticles with MPC polymers, researchers can make substances that are easily transported and delivered into the blood or other tissue because […]

Filed Under: Featured, Nanoparticles, Research & Development Tagged With: University of Tokyo

NanoViricides inks deal for shingles study

November 1, 2016 By Sarah Faulkner

Nanoviricides inks deal for shingles study

NanoViricides, Inc. (NYSE:NNVC) said today that it inked a deal with SUNY Upstate Medical University for the evaluation of its nanovirivides drug candidates against varicella zoster virus, also called the shingles virus. The goal of these in vitro, ex vivo, and in vivo studies will be to help select a clinical drug development candidate for toxicology and safety evaluation […]

Filed Under: Business/Financial News, Clinical Trials, Featured, Nanoparticles Tagged With: NanoViricides Inc

Cerulean promotes Eliasof to senior VP & CSO  | Personnel Moves, Oct. 26, 2016

October 26, 2016 By Sarah Faulkner

Scott Eliasof

Cerulean promotes Eliasof to senior VP & CSO Cerulean Pharma (NSDQ:CERU) said today that it named Scott Eliasof as senior VP and CSO, promoting him from VP of research. He joined the Waltham, Mass.-based company in 2007. Before coming on board to Cerulean, Eliasof was the director of the chemical biology platform at the Broad […]

Filed Under: Nanoparticles, Personnel Tagged With: Cerulean Pharma Inc.

Jivana Biotechnology raises $1m for targeted cancer therapy

October 26, 2016 By Sarah Faulkner

Jivana Biotechnology

Jivana Biotechnology raised $1 million for its preclinical work using targeted RNA-based therapies to treat a variety of cancers, according to a regulatory filing the Oak Park, Ill.-based company submitted this week. The minimum investment from an outside investor was $50,000, the company reported, and it used an estimated $125,000 for payments to its executive […]

Filed Under: Featured, Funding Roundup, Nanoparticles, Oncology Tagged With: Jivana Biotechnology

Bacterial nanostructures developed to locally deliver proteins

October 24, 2016 By Sarah Faulkner

Bacterial nanostructures developed to locally deliver proteins

Spanish researchers demonstrated that bacterial inclusion bodies, non-toxic nanostructures, hold promise for a sustained, local delivery of protein drugs by mimicking components of a mammal’s endocrine system. New materials developed as controllable, localized systems of drug delivery often aim to be immobilized in a given tissue as a drug “depot” for long term supply of […]

Filed Under: Featured, Nanoparticles, Oncology, Research & Development

Solid drug nanoparticles could improve delivery of HIV therapies

October 21, 2016 By Sarah Faulkner

Researchers from the University of Liverpool have developed a method of delivering pediatric HIV drugs using solid drug nanoparticles, according to a study published today in Nature Communications.  There are no clinically available oral nanotherapies for HIV patients and pediatric HIV medicines are not widely available, according to the researchers. The team examined a current pediatric […]

Filed Under: Featured, Nanoparticles, Research & Development Tagged With: University of Liverpool

Gold nanoparticles hold promise for pancreatic cancer treatment

October 21, 2016 By Sarah Faulkner

Gold nanoparticles could be an important part of developing a treatment for pancreatic cancer, according to new research published yesterday in the journal ACS Nano.  Previous work demonstrated that gold nanoparticles can be an effective vehicle to carry chemotherapy drugs into tumors. They can also act as a target to enhance the impact of radiation on […]

Filed Under: Drug-Device Combinations, Featured, Nanoparticles, Oncology, Research & Development

Cerulean, Novartis ink $5m deal to co-develop nanoparticle-drug conjugates

October 20, 2016 By Sarah Faulkner

Cerulean Pharma, Novartis

UPDATED Oct. 20, 2016, with Cerulean share price movement. Cerulean Pharma Inc. (NSDQ:CERU) said today that it inked a deal with Novartis (NYSE:NVS) to develop nanoparticle-drug conjugates. The products will match Cerulean’s tumor-targeting tech with Novartis compounds directed at up to 5 targets. The agreement calls for Cerulean to receive $5 million plus funding for 5 full-time equivalents […]

Filed Under: Nanoparticles, Pharmaceuticals Tagged With: Cerulean Pharma Inc., Novartis

Keystone Nano wins orphan designation for ceramide liver cancer treatment

October 18, 2016 By Sarah Faulkner

Keystone Nano launches clinical trial for NanoLiposome cancer therapy

Keystone Nano said today that its ceramide nanoliposome won orphan drug status from the FDA for the treatment of liver cancer. The designation provides the company with a window of market exclusivity after product approval. The State College, Penn.-based company touted its nanoliposome delivery system as being able to load both water-loving and water-hating compounds and […]

Filed Under: Featured, Food & Drug Administration (FDA), Nanoparticles, Oncology, Regulatory/Compliance Tagged With: Keystone Nano

Report finds ethosomes as promising transdermal delivery mechanism

October 7, 2016 By Sarah Faulkner

Ethosomes as promising transdermal delivery mechanism

Ethosomes – nanocarriers loaded with ethanol – can penetrate the skin’s protective layers and deliver a variety of drugs, a review published in Current Clinical Pharmacology reported today. Transdermal delivery of drugs is touted by some researchers as promising, since it’s noninvasive and avoids any interaction with the gastrointestinal tract. Ethosomes are malleable and their […]

Filed Under: Clinical Trials, Featured, Nanoparticles, Preclinical Trials, Research & Development

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS